With its sole remaining asset having failed to even enter the clinic, Ampio Pharmaceuticals has decided to call it a day.
It looks like Ampio Pharmaceuticals’ last shot at getting a therapy to market won’t even make it into the clinic. Animal studies have shown that the Colorado biotech’s OA-201 program was unable to reduce pain caused by osteoarthritis.
Ampio Pharmaceuticals to Present at the Emerging Growth Conference